4D Molecular Therapeutics Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, 4D Molecular Therapeutics Inc had 72.49M in cash and cash equivalents.

4D Molecular Therapeutics Inc reported 61.05M in total liabilities as of the latest reported quarter, including 43.98M in current liabilities and 17.06M in non-current liabilities.

As of the latest reported quarter, 4D Molecular Therapeutics Inc's total assets were 566.71M, consisting of 413.13M in current assets and 153.58M in non-current assets.

4D Molecular Therapeutics Inc reported 505.66M in total shareholders' equity as of the latest reported quarter.